Royalty Pharma plc: Royalty Pharma Reports Q4 and Full Year 2024 Results
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...
AdvancedMD Rolls Out 20+ Product Updates, Including Improved Patient Cards and New Population Health Reports
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.Da3GqCks.js ...
Clearwater Once Again Rated Healthcare's Top Cybersecurity Consultants
Clearwater, the largest pure-play provider of cybersecurity and compliance solutions for the healthcare industry, is proud to ...
Biohaven Ltd.: Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression ...